Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2011-08-16
2011-08-16
Young, Shawquia (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S081000
Reexamination Certificate
active
07998972
ABSTRACT:
The invention relates to the use of imidazoquinolines and salts thereof in the treatment of protein kinase dependent diseases and for the manufacture of pharmaceutical preparations for the treatment of said diseases, imidazoquinolines for use in the treatment of protein kinase dependent diseases, a method of treatment against said diseases, comprising administering the imidazoloquinolines to a warm-blooded animal, especially a human, pharmaceutical preparations comprising an imidazoquinoline, especially for the treatment of a protein kinase dependent disease, novel imidazoquinolines, and a process for the preparation of the novel imidazoquinolines.
REFERENCES:
patent: 4689338 (1987-08-01), Gerster
patent: 4698348 (1987-10-01), Gerster
patent: 5525612 (1996-06-01), Gerster
patent: 5605899 (1997-02-01), Gerster
patent: 145340 (1985-06-01), None
patent: 0145340 (1985-06-01), None
patent: 307078 (1989-03-01), None
patent: 0310950 (1989-04-01), None
patent: 386722 (1990-09-01), None
patent: 0389302 (1990-09-01), None
patent: 441036 (1990-12-01), None
patent: 1104764 (2001-06-01), None
patent: 1256582 (2002-11-01), None
patent: 11080156 (1997-09-01), None
patent: WO 9215582 (1992-09-01), None
patent: WO 99/09029 (1999-02-01), None
patent: WO 0009506 (2000-02-01), None
patent: WO 0055154 (2000-09-01), None
patent: WO 0076519 (2000-12-01), None
patent: WO 0146190 (2001-06-01), None
patent: WO 01/97795 (2001-12-01), None
patent: WO 0246188 (2002-06-01), None
Brown, T.H. et al., Journal of Medicinal Chemistry, American Chemical Society, 33, pp. 527-533 (1990).
U.S. Appl. No. 10/579,867, commonly assigned to Novartis.
U.S. Appl. No. 11/913,788, commonly assigned to Novartis.
Kato, et al. (Document No: 132: 180573) retrieved from Caplus on Jun. 7, 2010.
Brown, et al. J. Med. Chem. 1990, 33, 527-533.
Isomers [online], [retrieved on Mar. 11, 2007]. Retrieved from the Internet, URL; http ://chemed.chem.purdue.edu/genchem/topicreview/bp/ I organic/isomers.html>.
Cancer and Metastasis Reviews (1998), 17(1), 91-106.
Science (1999), vol. 286, 531-537.
Cancer [online], [retrieved on Jul. 6, 2007]. Retrieved from the internet, URL http://www.nlm.nih.gov/medlineplus/cancer.html>.
Cancer [online], [retrieved on Jul. 6, 2007]. Retrieved from the internet, URL; http://en.wikipedia.orglwikilCancer.
Megyeri, K. et al., Molecular and Cellular Biology, 15, No. 4, pp. 2207-2218 (Apr. 1, 1995).
Lee, J.C. et al., Nature, 372, pp. 739-746 (Dec. 22, 1994).
Brown, T.H. et al., Journal of medicinal Chemistry, American Chemical Society, 33, pp. 527-533 (1990).
R.L.A. Bottrel et al., Antimicrobial Agents and Chemotherapy, American Society for Microbiology, 43, No. 4., pp. 856-861 (Apr. 1999).
G.A. Bishop et al., The Journal of Immunology, 165, No. 10, pp. 5552-5557 (2000).
Capraro Hans-Georg
Furet Pascal
Garcia-Echeverria Carlos
Gilholm Steve
Novartis AG
Smith Michael G.
Young Shawquia
LandOfFree
1H-imidazo[4,5-c]quinoline derivatives in the treatment of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 1H-imidazo[4,5-c]quinoline derivatives in the treatment of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 1H-imidazo[4,5-c]quinoline derivatives in the treatment of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2781336